PIM
REGN icon

Partner Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Partner Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-600
Closed -$241K – 111
2016
Q3 		$241K Sell
600
-1,300
-68% -$521K 0.36% 69
2016
Q2 		$664K Buy
+1,900
New +$732K 1.09% 43

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Partner Investment Management's REGN Position: Q1 2018 in Review

Partner Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 3,555 shares — an estimated $1.34M sold.

Partner Investment Management first reported a position in REGN in Q2 2013 and held it in 4 quarters. The position peaked at $5.7M in Q3 2013. 620 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

  • Partner Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Partner Investment Management sold 3,555 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $1.34M.
  • Partner Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Partner Investment Management's Regeneron Pharmaceuticals position peaked at $5.7M in Q3 2013.
  • 620 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Partner Investment Management's 13F filing for Q1 2018, filed 15 May 2018.